A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2120 participants.

Also called NCT04255602

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04255602
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04255602. Randomized; no masking; primary purpose treatment. Start 2020-02-19 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients
Acronym
TIGER
Condition
Acute Coronary Syndrome
Condition
Coronary Stent Implantation
Intervention (Drug)
Ticagrelor 60mg
Intervention (Drug)
Ticagrelor 90mg
Lead sponsor
Shanghai Tong Ren Hospital (class: other)
Collaborator
Shanghai Jiao Tong University School of Medicine (class: other)
Collaborator
Fudan University (class: other)

Record details

Record id
cardio:ct-nct04255602
Content hash
4e6aee11f7d2ce677a8ea4e47a2975e5f7df59cd86638b4a62d0a63754ffb3c2